Key Takeaways
- Replimune received its second FDA rejection for RP1 advanced melanoma treatment
- The therapy was under evaluation as a combination treatment with Bristol Myers Squibb’s (BMY) Opdivo
- FDA maintained its position that the clinical trial failed to meet “adequate and well-controlled” standards
- Shares of REPL plummeted approximately 19% to $4.76, with trading halted twice for volatility
- Current trading price represents a significant decline from the 52-week peak of $13.24
Replimune (REPL) has encountered its second regulatory hurdle from the FDA, as the agency maintained its position regarding deficiencies in the clinical trial framework supporting the drug application.
The regulatory agency delivered a complete response letter rejecting approval for RP1, scientifically designated as vusolimogene oderparepvec, intended for combination therapy with Bristol Myers Squibb’s (BMY) Opdivo in treating advanced melanoma patients who had undergone prior anti-PD-1 therapy.
According to the correspondence sent to Kari Jeschke, Replimune’s senior VP of regulatory affairs, the FDA determined that supplementary exploratory analysis of trial results failed to change its previous assessment. The RPL-001-16 study was found to fall short of qualifying as an adequate and well-controlled clinical investigation.
Notably, the FDA expressed no apprehensions regarding the treatment’s safety profile — the primary obstacle continues to be the evidence supporting efficacy.
This marks the second time regulators have turned down the application. The initial rejection occurred in July 2025, following Vinay Prasad’s appointment to head the FDA’s Center for Biologics Evaluation and Research by two months. Following the first setback, Replimune filed a revised Biologics License Application, which gained acceptance for regulatory review in October 2025.
Shares of REPL declined roughly 19% to reach $4.76 following the announcement. Market volatility triggered two trading suspensions throughout the session. Based on Dow Jones Market Data, this trajectory positions the stock toward its weakest closing price since October.
Trading at this level places REPL considerably beneath its 52-week peak of $13.24.
Understanding RP1 Therapy
RP1 represents a bioengineered variant of Herpes Simplex Virus type 1 — the identical pathogen responsible for cold sores. The company’s scientists modified the virus to selectively replicate within cancerous cells, leading to cell destruction while simultaneously activating an enhanced immune system response through white blood cell recruitment.
This treatment serves as the primary candidate within Replimune’s RPx platform, dedicated to developing oncolytic immunotherapies targeting solid tumor cancers.
The organization currently maintains a market capitalization of approximately $393 million. Due to ongoing negative earnings — typical for clinical-stage biotechnology firms developing their therapeutic pipelines — no P/E ratio is available.
Management Trading Activity and Corporate Finances
Replimune’s GF Score registers at 40 out of 100, featuring a profitability metric of merely 1 out of 10. The company’s financial strength assessment stands at 6 out of 10.
During the previous three-month period, company insiders disposed of $0.1 million in shares, while no insider purchases were documented.
The stock currently trades at $4.76, representing a substantial discount from the 52-week high of $13.24 reached earlier this year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
